AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site
NegativeHealth

AstraZeneca has paused its plans for a $271 million expansion of its research facility in Cambridge, following a previous investment cancellation in Liverpool.
Editor’s Note: This decision is significant as it reflects the company's shifting priorities and could impact local economies and job opportunities in the U.K. The halted expansion raises concerns about the future of pharmaceutical investments in the region.
— via World Pulse Now AI Editorial System